Brexit: Companies Must ‘Act Now’ To Avoid Drug Supply Disruptions In 2021
First Ferry Tickets About To Be Released
In its latest letter to medicines and medical product companies, the UK's Department of Health and Social Care says the biggest potential cause of disruption to supplies could be failure to prepare for border controls implemented by the EU member states after the end of the Brexit transition period.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The pharmaceutical industry has welcomed a decision to allow more time to bring in new medicines regulations in Northern Ireland, but continues to insist that a mutual recognition agreement between the UK and the EU on drug manufacturing is the best way forward.
As negotiators struggle to reach agreement on the future UK/EU relationship, pharma firms have been warned to expect major hold-ups next year for medicines crossing the Channel.